Aurora Cannabis Inc Dossier
Qualitative Analysis
Business overview
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a global pioneer and leader in the cannabis industry, primarily serving international and domestic medical cannabis markets. Headquartered in Edmonton, Alberta, Canada, the company has established a robust footprint spanning 25 countries across five continents. Aurora's core strategic focus is on high-margin, pharmaceutical-grade medical cannabis cultivation and distribution, leveraging a brand portfolio that includes Aurora, CanniMed, MedReleaf, and Pedanios. Following a major corporate restructuring, the company has streamlined its operations to focus almost exclusively on global medical markets, while systematically winding down its lower-margin Canadian consumer recreational business and divesting non-core assets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing resources on high-margin international medical cannabis markets, particularly Germany, Poland, Australia, and the UK, where patient access and demand are growing rapidly.
Expected impact: Aims to drive double-digit growth in international medical sales to offset domestic Canadian reimbursement headwinds.
Exiting the lower-margin Canadian consumer cannabis segment to prioritize higher-margin global medical cannabis operations.
Expected impact: Expected to lower adjusted SG&A expenses and improve consolidated adjusted gross margins due to lower marketing and sales costs associated with consumer segments.
Integrating the newly acquired Safari Flower Company's 59,000 square foot indoor facility to scale up the supply of high-quality, EU GMP-compliant flower.
Expected impact: Expected to deliver positive adjusted EBITDA contributions in FY2027 and improve operational yields and supply chain efficiencies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand EU GMP-certified indoor cultivation and manufacturing capacity in Ontario, Canada, to supply high-potency medical flower to growing international markets like Germany, Poland, Australia, and the UK.
Financial impact: Acquired for $26.5 million (composed of $15 million in cash and 2,417,180 common shares valued at approximately $11.5 million, with an additional $2 million cash payment contingent on certain conditions).
Acquisition of the remaining ~90% equity interest in Indica Industries Pty Ltd (MedReleaf Australia) to solidify Aurora's position as the largest global medical cannabis company and accelerate plans for positive free cash flow.
Financial impact: Acquired at an enterprise value of AUD 50 million (approximately CAD 44.3 million), paid via AUD 9.45 million in cash and the balance in Aurora common shares.
Strategic Partnerships
Expands patient access to Aurora's medical cannabis portfolio (including MedReleaf, CraftPlant, Aurora, Whistler, and IndiMed brands) across Australia through Leafio's nationwide supply chain servicing over 4,000 pharmacies.
Terms: Not disclosed
Breathe Life Sciences will manufacture pharmaceutical-grade medical cannabis products (starting with sublingual oils and expanding to GMP-manufactured vapes) for export to Australia, the UK, and Germany under Aurora's portfolio.
Terms: Initial purchase orders received for over 5,000 sublingual oil products and over 20,000 vape products.
Broadens distribution of Aurora's medical cannabis products (under CraftPlant, Aurora, and IndiMed brands) to pharmacies across Australia.
Terms: Not disclosed